Zobrazeno 1 - 10
of 2 582
pro vyhledávání: ''
Autor:
Nicholas Matsumoto, Kai-Han Tu, Shoujie Chai, Chen-Ching Peng, Benjamin Ormseth, Katherine Cunningham, Ana Aparicio, Rafael Nevarez, Ching-Ju Hsu, Ryan Storgard, Peter Kuhn, Paymaneh D. Malihi, Kate Rappard, Anand Kolatkar, Carmen Ruiz-Velasco, Amado J. Zurita, Paul G. Corn, James W. Hicks
Publikováno v:
Molecular Cancer Research. 19:2036-2045
Metastatic castration-resistant prostate cancer (mCRPC) includes a subset of patients with particularly unfavorable prognosis characterized by combined defects in at least two of three tumor suppressor genes: PTEN, RB1, and TP53 as aggressive variant
Autor:
Lyndsey S. Crump, Traci R. Lyons, Elena Shagisultanova, Peter Kabos, Virginia F. Borges, Aryana R Rasti, Michelle Borakove, Benjamin A Harrison, Jessica K. Hall
Publikováno v:
Mol Cancer Ther
Breast cancers that express hormonal receptors (HR) and HER2 display resistance to targeted therapy. Tumor-promotional signaling from the HER2 and estrogen receptor (ER) pathways converges at the cyclin D1 and cyclin-dependent kinases (CDK) 4 and 6 c
Autor:
Sajid Khan, Abderrahmane Tagmount, Elizabeth A. Williamson, Xuan Zhang, Dinesh Thummuri, Vivekananda Budamagunta, Ashwin Akki, Jose G. Trevino, Janet S. Wiegand, Daohong Zhou, Amin Sobh, Peiyi Zheng, Guangrong Zheng, Alex Loguinov, Chris D. Vulpe, Andrea N. Riner, Patrick W. Underwood, Robert Hromas
Publikováno v:
Molecular Cancer Therapeutics. 21:184-192
Pancreatic cancer is the third most common cause of cancer-related deaths in the United States. Although gemcitabine is the standard of care for most patients with pancreatic cancer, its efficacy is limited by the development of resistance. This resi
Autor:
Andrew D MacKinnon, Sabine Mueller, Sara Temelso, Ashirwad Merve, Alan Mackay, Reda Stankunaite, Chris Jones, Daniel P. Smith, Safa Al-Sarraj, Andres Morales La Madrid, Jacques Grill, Adam Donovan, Ofelia Cruz, Mike Hubank, David Sheppard, Cinzia Lavarino, Anne Phelan, Bassel Zebian, Valeria Molinari, Angel M. Carcaboso, Diana Carvalho, Jeremy Pryce, Elizabeth A Corley, Fernando Carceller, Ruth Ruddle, Nagore G. Olaciregui, Akos Pal, Florence I. Raynaud, Peter John Richardson, John P. Overington
Publikováno v:
Cancer Discovery. 12:416-431
Somatic mutations in ACVR1 are found in a quarter of children with diffuse intrinsic pontine glioma (DIPG), but there are no ACVR1 inhibitors licensed for the disease. Using an artificial intelligence–based platform to search for approved compounds
Autor:
Cory Abate-Shen, Amir Lankarani, Matteo Di Bernardo, Michael M. Shen, Rivka L. Shoulson, Soonbum Park, Lijie Rong, Tomasz Owczarek, Talal Syed, Hikmat Al-Ahmadie, David B. Solit, James M. McKiernan, Chee-Wai Chua, Prithi Chakrapani, Jaime Y. Kim
Publikováno v:
Cancer Res
To study the progression of bladder cancer from non–muscle-invasive to muscle-invasive disease, we have developed a novel toolkit that uses complementary approaches to achieve gene recombination in specific cell populations in the bladder urotheliu
Autor:
Konstantinos N. Syrigos, Sebastien Guillaume, George Fountzilas, Saba Shafi, Henry L. Gomez, Aileen Fernandez, David L. Rimm, Nadia Harbeck, Serena Di Cosimo, Lajos Pusztai, Yingbo Wang, Paolo Nuciforo, Sung Bae Kim, Christos Sotiriou, Ioannis A. Vathiotis, Myrto Moutafi, Thazin Nwe Aung, Sarra El-Abed, Prajan Divakar, Jens Huober, Sarah Warren, Tao Qing, Vesal Yaghoobi
Publikováno v:
Clin Cancer Res
Purpose: The companion diagnostic test for trastuzumab has not changed much in the last 25 years. We used high-plex digital spatial profiling to identify biomarkers besides HER2 that can help predict response to trastuzumab in HER2-positive breast ca
Autor:
Kenji M Fujihara, Nicholas J Clemons, Sue Haupt, Bonnie Z Zhang, Hyun S Ko, Mariana Corrales Benitez, Kaylene J. Simpson, Wayne A. Phillips, David Shi Hao Liu, Carlos S. Cabalag, Lara Lipton, Ygal Haupt
Publikováno v:
Molecular Cancer Therapeutics. 20:1858-1867
APR-246 (eprenetapopt) is in clinical development with a focus on hematologic malignancies and is promoted as a mutant-p53 reactivation therapy. Currently, the detection of at least one TP53 mutation is an inclusion criterion for patient selection in
Publikováno v:
Cancer Res
Myelofibrosis (myelofibrosis) is a deadly blood neoplasia with the worst prognosis among myeloproliferative neoplasms (MPN). The JAK2 inhibitors ruxolitinib and fedratinib have been approved for treatment of myelofibrosis, but they do not offer signi
Publikováno v:
Clinical Cancer Research. 27:5457-5464
The recent advances in the field of immuno-oncology have dramatically changed the therapeutic strategy against advanced malignancies. Bispecific antibody-based immunotherapies have gained momentum in preclinical and clinical investigations following
Autor:
Mikhail G. Dozmorov, Richard Kurupi, Bin Hu, Colleen Casey, Jinyang Cai, Krista M. Dalton, Yael P. Mosse, Alessia D'Aulerio, Patricia Greninger, Cyril H. Benes, Timonthy L. Lochmann, Renata Sano, Colin M. Coon, Andrew J. Souers, Sheeba Jacob, Qasim A Khan, Anthony C. Faber, Kateryna Krytska, Giovanna Stein Crowther
Publikováno v:
Molecular Cancer Therapeutics. 20:1400-1411
Venetoclax is a small molecule inhibitor of the prosurvival protein BCL-2 that has gained market approval in BCL-2–dependent hematologic cancers including chronic lymphocytic leukemia and acute myeloid leukemia. Neuroblastoma is a heterogenous pedi